A clinically validated AI framework for kidney cancer detection and characterization
To the best of our knowledge, BMVision is the first clinically validated commercial artificial intelligence tool for kidney cancer detection and characterization. By improving diagnostic accuracy and reporting efficiency, it has the potential to enhance patient care and help radiologists meet the growing demand for high-quality cancer diagnostics.
Authors
- Toomas Lillsaar
- M. Reim
- Dmytro Fishman (ORCID: https://orcid.org/0000-0002-4644-8893)
- Pilvi Ilves (ORCID: https://orcid.org/0000-0002-0094-4998)
- Bohdan Petryshak
- Alina Denissova
- Joonas Ariva (ORCID: https://orcid.org/0009-0003-7171-7359)
- Anu Leht
- Anti Karask
- Rait Käpp
- Mikhail Iljin
- Toomas Häide
- Gitana Kiudma
- Priit Salumaa
- Ihor Ivaniv
- Hardi Vilt
- Veljo Lasn
Institutions
- Tallinn University (EE)
- Tartu University Hospital (EE)
- Better Education Inc (US)
- Ukrainian Catholic University (UA)
- Software Technology and Applications Competence Center (EE)
- University of Tartu (EE)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1038/s43856-025-01264-0
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tartu Ülikool